HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ouch! Two UK Analgesic Ad Complaints: Reckitt Rapped, Perrigo Pardoned

Executive Summary

Two UK advertising complaint verdicts delivered by the MHRA, Reckitt Benckiser's Nurofen Express (upheld) and Perrigo's Solpadeine Max (not upheld).

You may also be interested in...

Perrigo Rapped Over Solpadeine Claim in UK, While Cleared Of Wrongdoing In Spanish XLS Ad

Perrigo has found itself in hot water with the UK's MHRA over claims made on the website of its Solpadeine pain-relief brand. Meanwhile, the company has been exonerated after complaints against a TV ad to promote its XLS weight-loss brand proved to be unfounded.

What's In A Name? Dextro Energy Stung By UK Ad Regulator For Implying Energy Boost

By the positioning of a pack shot of its eponymous glucose supplement in a recent advertisement, Dextro Energy had implied the product could deliver an instant energy boost - which it was not authorized to do, ruled UK watchdog ASA. 

ASA Clears RB Of Misleading UK Consumers In Two Nurofen Ads

The UK's Advertising Standards Authority has cleared Reckitt Benckiser of misleading British consumers with two advertisements for its Nurofen brand of analgesics.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts